ghk cu immunogenicity antibody formation GHK-CU – Peptide Foundry Figure 2 from GHK –

BMJ 2021:372

In human splenocyte cultures, IL-2 levels rose significantly within just five hours of exposure [17]

For example, more than 30% of patients using GLP-1 therapies for obesity discontinue within the first month and nearly 60% stop within three months, underscoring the importance of identifying and prioritizing potential high-risk periods for proactive monitoring and targeted intervention, if needed

doi: 10.1007/s11695-015-1952-8

Understanding GHK-CU mechanisms requires examining how this tripeptide interacts with copper and cellular receptors

Regulatory Note on Injectable GHK-Cu It is important to note that the FDA added injectable GHK-Cu to a high-risk compounded substance list in September 2023